Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University for experiments demonstrating the value of pre-conditioning biomass prior to distillation; Cesar for assessing the insecticidal activity of its molecules against a range of insect species; Advanced Molecular Technologies; CSIRO for a chemistry development process; the Department of Agriculture and Fisheries, Queensland Government for assessing activity against grain storage pests; Eurofins; Grain Research Development Corporation; Pacific Discovery Services; Purdue University; Southern Cross University for chemical analysis of natural products; University of Florida; and University of Technology. It serves animal health, crop protection, grain storage, public health, and consumer applications. The company was incorporated in 1995 and is based in Melbourne, Australia.
Research context
Bio-Gene Technology Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Bio-Gene Technology Limited is currently in a long term uptrend where the price is trading 15.4% above its 200 day moving average.
From a valuation standpoint, the stock is 91.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.0.
Bio-Gene Technology Limited's total revenue sank by 82.3% to $89K since the same quarter in the previous year.
Its net income has dropped by 25.3% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 42.6% to $-245K since the same quarter in the previous year.
Based on the above factors, Bio-Gene Technology Limited gets an overall score of 3/5.